GlassScriptPhysician profile
Susan M Constantino
NPI 1831317940
$4,638.61
in general payments reported to CMS, 2019-2025
33 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $584 · 2021: $351 · 2022: $110 · 2023: $705 · 2024: $680 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839 · Consulting Fee: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.94 |
| Consulting Fee | $1,160.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,218.91 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $635.05 | 2020-2025 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $339.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $256.89 | 2019-2024 | Pomalyst, Opdivo |
| Seagen INC. | $227.23 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $198.80 | 2020-2021 | |
| Sobi, INC | $158.49 | 2023-2024 | |
| Celgene Corporation | $134.09 | 2021 | |
| Emd Serono, INC. | $129.62 | 2024 | |
| Karyopharm Therapeutics INC. | $124.61 | 2020 | |
| Amag Pharmaceuticals, INC. | $119.56 | 2019 | |
| Abbvie INC. | $116.27 | 2019 | |
| Astellas Pharma US INC | $114.28 | 2020 | |
| Pharmaessentia USA Corporation | $110.06 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $88.92 | 2023 | Tazverik |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $78.87 | 2024-2025 | Rybrevant, Darzalex |
| Merck Sharp & Dohme LLC | $78.36 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Puma Biotechnology, INC. | $52.04 | 2024-2025 | |
| Genentech USA, INC. | $50.85 | 2021-2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $49.43 | 2024-2025 | Fruzaqla |
| Pfizer INC. | $45.86 | 2024 | |
| Tersera Therapeutics LLC | $33.45 | 2023 | Zoladex |
| Novocure INC. | $32.50 | 2023 | |
| Stryker Corporation | $30.59 | 2025 | Spy-Phi System |
| Sun Pharmaceutical Industries INC. | $30.13 | 2024 | |
| Blueprint Medicines Corporation | $28.63 | 2024 | Ayvakit |
| Agios Pharmaceuticals, INC. | $26.44 | 2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $24.07 | 2025 | |
| Lilly USA, LLC | $23.87 | 2024 | Verzenio, Jaypirca, Retevmo |
| Array Biopharma INC | $23.61 | 2024 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $21.57 | 2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $18.70 | 2024 | |
| Recordati_rare_diseases_inc. | $17.42 | 2024 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Constantino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.